OTCMKTS:CHGCY

Chugai Pharmaceutical (CHGCY) Stock Forecast, Price & News

$14.31

+0.01 (+0.07%)

(As of 09/22/2023 ET)

Compare

Today's Range: $13.89
▼
$14.79
50-Day Range: $13.92
▼
$15.43
52-Week Range: $10.99
▼
$15.86

Volume: 81,205 shs
Average Volume: 49,643 shs
Market Capitalization: $47.08 billion

P/E Ratio: 16.26
Dividend Yield: 1.40%
Price Target: N/A

Profile Analyst Ratings Chart Competitors Earnings Financials Headlines SEC Filings Short Interest

Chugai Pharmaceutical MarketRank™ Forecast

Analyst Rating: N/A
Upside/Downside: N/A
Short Interest: Healthy
0.00% of Shares Sold Short
Dividend Strength: Moderate
Based on Four Factors
Sustainability: N/A
News Sentiment: N/A
Insider Trading: N/A
Proj. Earnings Growth: -7.69%
From $2.73 to $2.52 Per Share

Overall MarketRank^™

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

1.43 out of 5 stars

N/A

Analyst's Opinion

Consensus Rating
There is not enough analysis data for Chugai Pharmaceutical.

3.0

Short Interest

Percentage of Shares Shorted
0.00% of the outstanding shares of Chugai Pharmaceutical have been sold short.
Short Interest Ratio / Days to Cover
Chugai Pharmaceutical has a short interest ratio ("days to cover") of 0.2, which is generally considered an acceptable ratio of short interest to trading volume.
Change versus previous month
Short interest in Chugai Pharmaceutical has recently increased by 22.52%, indicating that investor sentiment is decreasing significantly.

2.5

Dividend Strength

Dividend Yield
Chugai Pharmaceutical pays a meaningful dividend of 1.37%, higher than the bottom 25% of all stocks that pay dividends.
Dividend Growth
Chugai Pharmaceutical does not have a long track record of dividend growth.
Dividend Coverage
The dividend payout ratio of Chugai Pharmaceutical is 22.73%. This payout ratio is at a healthy, sustainable level, below 75%.
Dividend Sustainability
Based on earnings estimates, Chugai Pharmaceutical will have a dividend payout ratio of 7.94% next year. This indicates that Chugai Pharmaceutical will be able to sustain or increase its dividend.

N/A

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
There is no current Upright™ data available for CHGCY.

0.6

News and Social Media Coverage

MarketBeat Follows
2 people have added Chugai Pharmaceutical to their MarketBeat watchlist in the last 30 days.

0.0

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Chugai Pharmaceutical insiders have not sold or bought any company stock.
Percentage Held by Institutions
Only 0.01% of the stock of Chugai Pharmaceutical is held by institutions.

1.3

Earnings and Valuation

Earnings Growth
Earnings for Chugai Pharmaceutical are expected to decrease by -7.69% in the coming year, from $2.73 to $2.52 per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of Chugai Pharmaceutical is 16.26, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 117.40.
Price to Earnings Ratio vs. Sector
The P/E ratio of Chugai Pharmaceutical is 16.26, which means that it is trading at a less expensive P/E ratio than the Medical sector average P/E ratio of about 143.17.
Price to Book Value per Share Ratio
Chugai Pharmaceutical has a P/B Ratio of 4.30. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

About Chugai Pharmaceutical (OTCMKTS:CHGCY) Stock

Chugai Pharmaceutical Co., Ltd., together with its subsidiaries, engages in the research, development, manufacture, sale, importation, and exportation of pharmaceuticals in Japan and internationally. The company's products for oncology primarily include Avastin, FoundationOne, Polivy, Rozlytrek, Tecentriq, Perjeta, Alecensa, Herceptin, Kadcyla, Rituxan, and Gazyva; Edirol, an Osteoporosis agent; Mircera, an erythropoiesis agent; Oxarol, an agent for secondary hyperparathyroidism; and other diseases comprise Hemlibra, CellCept, Bonviva, Tamiflu, Evrysdi, Ronapreve, Vabysmo, and Enspryng. It has various development product candidates in the areas of oncology, immunology, neuroscience, hematology, ophthalmology, and other diseases. Chugai Pharmaceutical Co., Ltd. has strategic alliances and collaboration with Roche Group. The company was founded in 1925 and is headquartered in Chuo, Japan. Chugai Pharmaceutical Co., Ltd. operates as a subsidiary of Roche Holding Ltd.

CHGCY Price History

30 days | 90 days | 365 days | Advanced Chart

CHGCY Stock News Headlines

September 1, 2023 | investing.com

TOPIX Pharmaceutical (IPHAM.T)

August 19, 2023 | wsj.com

Chugai Pharmaceutical Co. Ltd.

September 24, 2023 | Behind the Markets (Ad)

3 Words and a 3,000% Return

In October 2013, a scientist wrote 3 words on a piece of paper. They were simple words. A fiveyear-old could say them. But these three words could deliver you a 3,000% return in 2023 >>>

August 3, 2023 | msn.com

Chugai Pharmaceutical (CHGCF) Price Target Decreased by 6.55% to 30.71

April 26, 2023 | markets.businessinsider.com

Here's what to expect from Chugai Pharmaceutical's earnings report

April 18, 2023 | seekingalpha.com

CHGCY Chugai Pharmaceutical Co., Ltd.

March 2, 2023 | msn.com

Chugai, Biofourmis expand team up on digital solutions to measure endometriosis pain

March 2, 2023 | finance.yahoo.com

Chugai and Biofourmis Enter into New Partnership Focused on Data-Driven Virtual Care for Endometriosis-Related Pain

September 24, 2023 | Behind the Markets (Ad)

3 Words and a 3,000% Return

In October 2013, a scientist wrote 3 words on a piece of paper. They were simple words. A fiveyear-old could say them. But these three words could deliver you a 3,000% return in 2023 >>>

December 30, 2022 | seekingalpha.com

Roche: Worthy Of Big Pharma Label, Maybe Not A 'Value Pick' Yet

December 14, 2022 | finance.yahoo.com

Visiox Pharma Announces FDA Acceptance of New Drug Application for Glaucoma

December 12, 2022 | benzinga.com

Short Volatility Alert: Chugai Pharm Co

April 27, 2022 | seekingalpha.com

Chugai Pharmaceutical reports Q1 results

April 25, 2022 | seekingalpha.com

Chugai Pharmaceutical Co., Ltd. 2022 Q1 - Results - Earnings Call Presentation

March 17, 2022 | msn.com

The Daily Biotech Pulse: AbbVie's Rinvoq Gets Label Expansion, AstraZeneca COVID Antibody Cocktail Authorized By UK Regulator, Stealth Touts Positive Data

March 17, 2022 | nasdaq.com

Has Chugai Pharmaceutical Co., Ltd. Unsponsored ADR (CHGCY) Outpaced Other Medical Stocks This Year?

October 14, 2021 | finance.yahoo.com

New Four-year Data Show Sustained Relapse Reduction by Chugai’s Enspryng in People With Neuromyelitis Optica Spectrum Disorder (NMOSD)

July 26, 2021 | seekingalpha.com

Chugai Pharmaceutical Co., Ltd. 2021 Q2 - Results - Earnings Call Presentation

June 28, 2021 | finance.yahoo.com

Chugai’s Enspryng (Satralizumab) Approved by European Commission as First At-home Subcutaneous Treatment for Neuromyelitis Optica Spectrum Disorder (NMOSD)

June 27, 2021 | investing.com

Chugai Pharmaceutical Co Ltd ADR (CHGCY)

April 22, 2021 | seekingalpha.com

Chugai Pharmaceutical Co., Ltd. 2021 Q1 - Results - Earnings Call Presentation

January 12, 2021 | msn.com

Global Markets Remain Mixed Amid China's Rally, Bitcoin Recovers

January 9, 2021 | finance.yahoo.com

Chugai Pharmaceutical Co., Ltd. (CHGCY)

December 9, 2020 | finance.yahoo.com

Chugai’s Enspryng Approved in Taiwan as First Approved Medicine for Neuromyelitis Optica Spectrum Disorder (NMOSD)

October 25, 2020 | seekingalpha.com

Chugai Pharmaceutical Co., Ltd. 2020 Q3 - Results - Earnings Call Presentation

October 21, 2020 | wsj.com

Chugai Pharmaceutical Co. Ltd. ADR

July 21, 2020 | markets.businessinsider.com

Chugai and Biofourmis Partner to Develop an Objective Assessment of Pain Using Digital Technology

See More Headlines

Receive CHGCY Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Chugai Pharmaceutical and its competitors with MarketBeat's FREE daily newsletter.

CHGCY Company Calendar

Today: 9/23/2023
Fiscal Year End: 12/31/2023

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: OTCMKTS
Industry: Drugs, proprietaries, & sundries
Sub-Industry: N/A
Sector: Medical
Current Symbol: OTCMKTS:CHGCY
CUSIP: N/A
CIK: 1453934
Web: www.chugai-pharm.co.jp
Phone: (133) 281-6611
Fax: N/A
Employees: 7,664
Year Founded: N/A

Profitability

EPS (Most Recent Fiscal Year): $0.88
Trailing P/E Ratio: 16.26
Forward P/E Ratio: 5.24
P/E Growth: N/A
Net Income: $2.88 billion
Net Margins: 30.12%
Pretax Margin: 42.16%
Return on Equity: 28.30%
Return on Assets: 22.05%

Debt

Debt-to-Equity Ratio: N/A
Current Ratio: 3.15
Quick Ratio: 2.46

Sales & Book Value

Annual Sales: $9.65 billion
Price / Sales: 4.88
Cash Flow: $0.95 per share
Price / Cash Flow: 15.13
Book Value: $3.33 per share
Price / Book: 4.30

Miscellaneous

Outstanding Shares: 3,289,980,000
Free Float: N/A
Market Cap: $47.08 billion
Optionable: Not Optionable
Beta: 0.63

10 Best Cheap Stocks to Buy Now

MarketBeat just released its list of 10 cheap stocks that have been overlooked by the market and may be seriously undervalued. Click the link below to see which companies made the list.

Get This Free Report

Key Executives

Dr. Osamu Okuda (Age 60)
Pres, CEO & Representative Director
Comp: $1.24M

Mr. Toshiaki Itagaki (Age 63)
Head of Fin. Supervisory Division, CFO, Exec. VP & Director

Toshiya Sasai
Exec. of Investor Relations Group & Corp. Communications Department

Mr. Shinji Hidaka
Exec. VP and Head of Marketing & Sales Division

Mr. Junichi Ebihara
Exec. VP

Dr. Yoshiaki Ohashi (Age 63)
SVP & Full-time Audit Supervisory Board Member

Mr. Tetsuya Yamaguchi
Exec. VP and Head of Project, Lifecycle Management & Foundation Medicine Unit

Mr. Yoshiyuki Yano
Exec. VP

Ms. Satoko Shisai
Exec. VP & Head of Digital Transformation Unit

Dr. Shigehiro Yamada Ph.D. (Age 59)
Head of Sustainability Department & Full-Time Audit & Supervisory Board Member

Key Competitors

View All Competitors

CHGCY Stock - Frequently Asked Questions

Should I buy or sell Chugai Pharmaceutical stock right now?: 1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Chugai Pharmaceutical in the last twelve months. There are currently 1 buy rating for the stock. The consensus among Wall Street analysts is that investors should "buy" CHGCY shares.
View CHGCY analyst ratings or view top-rated stocks.
How have CHGCY shares performed in 2023?: Chugai Pharmaceutical's stock was trading at $12.67 on January 1st, 2023. Since then, CHGCY stock has increased by 12.9% and is now trading at $14.31.
View the best growth stocks for 2023 here.
Are investors shorting Chugai Pharmaceutical?: Chugai Pharmaceutical saw a increase in short interest during the month of August. As of August 31st, there was short interest totaling 32,100 shares, an increase of 22.5% from the August 15th total of 26,200 shares. Based on an average trading volume of 143,300 shares, the short-interest ratio is currently 0.2 days.
View Chugai Pharmaceutical's Short Interest.
Is Chugai Pharmaceutical a good dividend stock?: Chugai Pharmaceutical (OTCMKTS:CHGCY) pays an annual dividend of $0.20 per share and currently has a dividend yield of 1.37%. The dividend payout ratio is 22.73%. This payout ratio is at a healthy, sustainable level, below 75%. Based on earnings estimates, CHGCY will have a dividend payout ratio of 7.94% next year. This indicates that the company will be able to sustain or increase its dividend.

What is Chugai Pharmaceutical's stock symbol?: Chugai Pharmaceutical trades on the OTCMKTS under the ticker symbol "CHGCY."
How do I buy shares of Chugai Pharmaceutical?: Shares of CHGCY stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.
What is Chugai Pharmaceutical's stock price today?: One share of CHGCY stock can currently be purchased for approximately $14.31.
How much money does Chugai Pharmaceutical make?: Chugai Pharmaceutical (OTCMKTS:CHGCY) has a market capitalization of $47.08 billion and generates $9.65 billion in revenue each year. The company earns $2.88 billion in net income (profit) each year or $0.88 on an earnings per share basis.
How many employees does Chugai Pharmaceutical have?: The company employs 7,664 workers across the globe.
How can I contact Chugai Pharmaceutical?: Chugai Pharmaceutical's mailing address is 15F, Nihombashi Mitsui Tower, Chuo Ku, Tokyo To 103-8324. The official website for the company is www.chugai-pharm.co.jp. The company can be reached via phone at (133) 281-6611.

This page (OTCMKTS:CHGCY) was last updated on 9/24/2023 by MarketBeat.com Staff

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial